{ "title": "Oral NIASPAN extended-release nicotinic acid — added to usual diabetes care × HbA1c increase in adults with stable type 2 diabetes and dyslipidemia", "criteria_version": "NGM-v3092-NIASPAN-HBA1C-INCREASE-1.0", "criteria_date": "2026-10-05", "method_sources": [ { "id": "M03", "version": "Cochrane Handbook 6.5 (2024), chapter updated 2023-08", "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-03", "section": "§3.1, §3.2.1–3.2.3, MECIR C5/C7/C13", "official_principle": "Clearly record the question, eligibility criteria, and reasons for changes, and distinguish variations in the intervention.", "review_level": "Reused the original HTML bytes/SHA copies and historical principles from 1585's 5 retained methods. This was not new full-text methods reading or official assessment/certification." }, { "id": "M04", "version": "Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03", "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-04", "section": "§4.5, §4.6.1–4.6.3, MECIR C42", "official_principle": "Distinguish studies from reports and link them; do not omit a study solely because results were not reported.", "review_level": "Reused the original HTML bytes/SHA copies and historical principles from 1585's 5 retained methods. This was not new full-text methods reading or official assessment/certification." }, { "id": "M08", "version": "Cochrane Handbook 6.5 (2024), chapter updated 2019-10", "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08", "section": "§8.1–8.2.3, Table 8.2.a", "official_principle": "Fix the outcome and effect of interest when reviewing randomization, departures, missing data, measurement, and selective reporting.", "review_level": "Reused the original HTML bytes/SHA copies and historical principles from 1585's 5 retained methods. This was not new full-text methods reading or official assessment/certification." }, { "id": "M15", "version": "Cochrane Handbook 6.5 (2024), chapter updated 2023-08", "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-15", "section": "§15.2.4, §15.3.1–15.3.3", "official_principle": "Distinguish effect estimates, intervals, importance, and application. Sample size alone does not determine precision.", "review_level": "Reused the original HTML bytes/SHA copies and historical principles from 1585's 5 retained methods. This was not new full-text methods reading or official assessment/certification." }, { "id": "M19", "version": "Cochrane Handbook 6.5 (2024), chapter updated 2019-10", "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-19", "section": "§19.1.2, §19.2.1–19.2.4", "official_principle": "Questions about harms may require designs, populations, and follow-up different from those for efficacy. Case reports do not establish incidence.", "review_level": "Reused the original HTML bytes/SHA copies and historical principles from 1585's 5 retained methods. This was not new full-text methods reading or official assessment/certification." } ], "status_dictionary": { "Met": "The specific narrow identity, definition, attribution of verified numbers, policy, or boundary of the actual record is verified. This does not certify clinical harm, a formal interval, or overall safety.", "Partly verified": "Some actual information is verified in the original material, but the product, denominator, analysis, or full estimate for the question remains incomplete.", "Unverified": "Cannot be established within the current retained scope. This does not mean an effect of 0, absence of studies worldwide, or current access failure.", "Conflicting information": "Original reports of the same fact do not agree. Successful recording of the conflict is distinguished from verification that the clinical data are consistent.", "Not reported": "Limited to nonreporting within the explicitly stated material accessed at the time. This is not a claim of absence throughout a full text left unread in this review.", "Not applicable": "Used when there is a specific reason why the applicability conditions of the current question are not met. Not a substitute for unverified or unread status.", "Inaccessible": "Historical failures are distinguished from actual current access failures. This status is not assigned to unattempted external access in this review.", "Review incomplete": "Limited to the current nonperformance of comparisons against external original material; distinguished from the local retained-summary review that was actually completed." }, "schema_version": "chamgap-public-criteria-1.0", "condition_origin": "Chamgap’s own application conditions", "requirements": [ { "item_id": "N01", "question_type": "Comparative harm: HbA1c increase", "question": "Which population, intervention, comparator, time period and endpoint define the comparative harm claim?", "needed": "Material linking the identity of the current claim with the actual population, intervention, comparator, endpoint and time point", "role": "Required", "role_reason": "Needed to distinguish the quantitative harm claim of an HbA1c increase from glycemic-improvement efficacy and a general safety indicator.", "application_exception": "Do not change the clinical-harm/increase classification (clinical_harm_claim/increase) to reduced efficacy or a safety-only flag (safety_only), or include other niacin interventions or other clinical endpoints.", "criterion": "The actual original material specifies the boundaries: stable type 2 diabetes and dyslipidemia, adjustable usual care, NIASPAN ER added versus matching placebo, and change over a total of 16 weeks in HbA1c.", "basis": "C01: Question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed / C04: M03 §3.2.1; detailed population criteria are internally designed / C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / H09: Chamgap's own interpretive boundaries. The M19 principles are referenced; no official causality tool was applied. Reason for adapting this to comparative HbA1c harm: needed to distinguish the quantitative harm claim of an HbA1c increase from glycemic-improvement efficacy and a general safety indicator. No new clinical causality/grade judgment or official methodological procedure was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Compare the current manuscript with the trial's actual comparison, and record the reason and the scope before and after any boundary change." }, { "item_id": "N02", "question_type": "Comparative harm: HbA1c increase", "question": "Are the actual ingredient, product, release formulation and route verified?", "needed": "The core trial's product name, ingredient, release formulation and route, and the corresponding locations in the official product description", "role": "Required", "role_reason": "Needed to avoid transferring results for NIASPAN extended-release nicotinic acid to nicotinamide or IR/SR formulations.", "application_exception": "Do not resolve an unverified separate salt designation by assuming equivalence to another salt. Distinguish the null value/not_applicable status for plant-part information (botanical_part) from the unverified manufacturing origin.", "criterion": "The original material distinguishes the single active ingredient nicotinic acid, NIASPAN (Kos), ER oral tablets, and the excluded molecules/formulations.", "basis": "C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application. Reason for adapting this to comparative HbA1c harm: needed to avoid transferring results for NIASPAN extended-release nicotinic acid to nicotinamide or IR/SR formulations. No new clinical causality/grade judgment or official methodological procedure was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Compare the trial product's ingredient and release formulation with the original description, and consider other molecules/formulations only through their own direct evidence." }, { "item_id": "N03", "question_type": "Comparative harm: HbA1c increase", "question": "Is the actual information on manufacturing origin, batch and excipients verified?", "needed": "Specifications for the trial product's manufacturing process, raw-material origin, batch and excipients", "role": "Supplementary; required for detailed product identity", "role_reason": "Knowing a product name and knowing its actual manufacturing origin, batch and excipients are different levels of information.", "application_exception": "Although plant-part information is not applicable to this chemical ingredient, do not change the unverified/null manufacturing origin to Not applicable.", "criterion": "Direct material is available to verify the selected product's manufacturing origin, batch and excipients.", "basis": "C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed. Reason for adapting this to comparative HbA1c harm: knowing a product name and knowing its actual manufacturing origin, batch and excipients are different levels of information. No new clinical causality/grade judgment or official methodological procedure was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "If permitted product material is obtained, compare it with the trial batch and do not inherit information from another product." }, { "item_id": "N04", "question_type": "Comparative harm: HbA1c increase", "question": "Are the trial's diagnosis, stability, age and inclusion/exclusion criteria verified?", "needed": "Inclusion/exclusion criteria, diagnosis, baseline-characteristics table and material verifying stability", "role": "Required", "role_reason": "Needed to avoid applying the selected trial's results unchanged to people with diabetes generally or to healthy people.", "application_exception": "Keep participants' baseline niacin-deficiency status separately unverified, and do not invent detailed subgroup effects.", "criterion": "The original material specifies age 21 or older, stable type 2 diabetes and dyslipidemia, diagnoses, entry criteria, sex and major exclusions.", "basis": "C04: M03 §3.2.1; detailed population criteria are internally designed / H05: Design considerations in M19 §19.2.2–19.2.4; detailed recording of confounding is internally designed. Reason for adapting this to comparative HbA1c harm: needed to avoid applying the selected trial's results unchanged to people with diabetes generally or to healthy people. No new clinical causality/grade judgment or official methodological procedure was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Compare the actual recruited population's diagnoses and entry criteria with the claim's target population, and keep direct results in other populations separate." }, { "item_id": "N05", "question_type": "Comparative harm: HbA1c increase", "question": "Are baseline niacin status, deficiency classification and total dietary intake verified?", "needed": "Baseline niacin measurements, deficiency-classification criteria and data on total dietary niacin", "role": "Supplementary; required for interpreting deficiency/total exposure", "role_reason": "Needed to avoid treating deficiency correction and prescription-drug addition in nondeficient participants as the same question.", "application_exception": "Do not extend information not identified in the text accessed at the time into a claim that it was unreported throughout the entire paper, or into evidence that deficiency was absent.", "criterion": "Participant-specific data are available on baseline niacin measurement, deficiency classification and total dietary intake.", "basis": "C04: M03 §3.2.1; detailed population criteria are internally designed / H05: Design considerations in M19 §19.2.2–19.2.4; detailed recording of confounding is internally designed. Reason for adapting this to comparative HbA1c harm: needed to avoid treating deficiency correction and prescription-drug addition in nondeficient participants as the same question. No new clinical causality/grade judgment or official methodological procedure was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Review direct material while distinguishing baseline status from drug and dietary exposure, and treat results of deficiency treatment as a separate question." }, { "item_id": "N06", "question_type": "Comparative harm: HbA1c increase", "question": "Are the actual planned titration, target dose and dosing frequency verified?", "needed": "Trial treatment schedule, target dose, tablet count and data on actual adherence/dose reached", "role": "Required", "role_reason": "Needed to avoid displaying the target dose as a fixed dose actually taken throughout the entire period.", "application_exception": "The study schedule is not a personal dosing instruction, and actual adherence/doses reached are distinguished from the planned titration schedule.", "criterion": "Bedtime administration at 1 dose per 1 day, weekly titration, target dose and tablet count are linked to the actual plan.", "basis": "C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed / H02: Design-specific harm questions in M19 §19.2; details of temporal relationships are internally designed. Reason for adapting this to comparative HbA1c harm: needed to avoid displaying the target dose as a fixed dose actually taken throughout the entire period. No new clinical causality/grade judgment or official methodological procedure was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Compare planned administration with actual treatment histories, distinguishing nominal dose, dose reached and cumulative exposure." }, { "item_id": "N07", "question_type": "Comparative harm: HbA1c increase", "question": "Are the titration period, target-dose period and total follow-up period separately identified and verified?", "needed": "Schedules for treatment, titration, target-dose maintenance and end of follow-up, together with long-term follow-up material", "role": "Required", "role_reason": "Needed to avoid turning the total of 16 weeks into fixed exposure to the target of 1,500 mg/day for 16 weeks, or into long-term follow-up.", "application_exception": "Do not use the planned 12-week target-dose period as a new clinical minimum duration or long-term safety criterion.", "criterion": "The planned total of 16 weeks, 4 weeks of titration and target dose in weeks 5–16 are distinguished from the absence of long-term follow-up.", "basis": "C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / H02: Design-specific harm questions in M19 §19.2; details of temporal relationships are internally designed / H08: M19 §19.1.2–19.2.4; internal application. Reason for adapting this to comparative HbA1c harm: needed to avoid turning the total of 16 weeks into fixed exposure to the target of 1,500 mg/day for 16 weeks, or into long-term follow-up. No new clinical causality/grade judgment or official methodological procedure was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Link the timeline to actual exposure and measurement schedules, and examine persistence after discontinuation or long-term outcomes through separate follow-up." }, { "item_id": "N08", "question_type": "Comparative harm: HbA1c increase", "question": "Is the actual composition of the matching placebo verified?", "needed": "Material on placebo manufacture, composition, appearance, corresponding tablets and blinding assessment", "role": "Required", "role_reason": "Needed to avoid turning the term matching placebo into verification of its exact ingredients or complete blinding.", "application_exception": "Do not use unverified placebo details as evidence that there was no placebo or as confirmation that blinding failed.", "criterion": "The matching placebo and a direct description of its composition, appearance and whether it contained active ingredients are verified.", "basis": "C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application / E02: M03 §3.2.3, M08 §8.2.2–8.2.3; internal application. Reason for adapting this to comparative HbA1c harm: needed to avoid turning the term matching placebo into verification of its exact ingredients or complete blinding. No new clinical causality/grade judgment or official methodological procedure was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Compare the placebo description with the trial product, distinguishing the unverified details of composition and blinding." }, { "item_id": "N09", "question_type": "Comparative harm: HbA1c increase", "question": "Are the common policies on diabetes-treatment adjustment, statins and aspirin verified?", "needed": "Trial rules for common care, diabetes-medication adjustment, statins and permitted aspirin use", "role": "Required", "role_reason": "Needed to distinguish a common policy from a claim that everyone actually received identical concomitant medication.", "application_exception": "Do not automatically judge diabetes-medication adjustment as contamination or design failure; preserve it as the care policy in the comparison of this add-on strategy.", "criterion": "Permission to change usual diabetes care, continuation of existing statins, the absence of a statin requirement for everyone, and the policy permitting but not requiring aspirin are verified.", "basis": "C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application / H05: Design considerations in M19 §19.2.2–19.2.4; detailed recording of confounding is internally designed / E02: M03 §3.2.3, M08 §8.2.2–8.2.3; internal application. Reason for adapting this to comparative HbA1c harm: needed to distinguish a common policy from a claim that everyone actually received identical concomitant medication. No new clinical causality/grade judgment or official methodological procedure was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Distinguish the common care policy from actual medication changes, include that policy in the effect of interest, and examine how departures by arm were handled." }, { "item_id": "N10", "question_type": "Comparative harm: HbA1c increase", "question": "Are the actual concomitant-treatment adjustments, adherence, rescue treatment and their analytical handling verified for each arm?", "needed": "Histories of changes to diabetes medications, statins and aspirin by arm, together with adherence, rescue-treatment and information on how these were handled in the analysis", "role": "Required", "role_reason": "Needed to avoid turning the observed add-on strategy into an isolated drug contribution under completely fixed diabetes medication.", "application_exception": "The existence of a policy permitting changes does not establish that the extent of changes by arm, adherence or the adjustment model was also verified.", "criterion": "Actual data verify concomitant-medication changes, attainment of the target dose, adherence/discontinuation and the corresponding analytical handling for each arm.", "basis": "H05: Design considerations in M19 §19.2.2–19.2.4; detailed recording of confounding is internally designed / E02: M03 §3.2.3, M08 §8.2.2–8.2.3; internal application / E04: M08 §8.2.2, M15 §15.3.1; internal application. Reason for adapting this to comparative HbA1c harm: needed to avoid turning the observed add-on strategy into an isolated drug contribution under completely fixed diabetes medication. No new clinical causality/grade judgment or official methodological procedure was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Compare actual treatment changes with the effect of interest for the add-on strategy, and examine how departures and adjustments by arm were handled in the analysis." }, { "item_id": "N11", "question_type": "Comparative harm: HbA1c increase", "question": "Are the actual methods for randomization, allocation concealment and baseline balance verified?", "needed": "The original randomization-sequence and allocation-concealment procedures, and the baseline-characteristics table by arm", "role": "Required; interpretation of comparative harm", "role_reason": "The labels RCT and double-blind alone cannot establish that sequence generation, concealment and selection differences have been addressed.", "application_exception": "Do not turn unverified concealment into actual absence of concealment or a confirmed bias defect. No new RoB grade is issued.", "criterion": "Material is available to verify the parallel-group design, random-sequence generation, allocation concealment and baseline balance.", "basis": "E01: M08 §8.1–8.2.3; internal application / H05: Design considerations in M19 §19.2.2–19.2.4; detailed recording of confounding is internally designed. Reason for adapting this to comparative HbA1c harm: the labels RCT and double-blind alone cannot establish that sequence generation, concealment and selection differences have been addressed. No new clinical causality/grade judgment or official methodological procedure was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Compare the allocation process with actual baseline balance, distinguishing verified methods from remaining gaps." }, { "item_id": "N12", "question_type": "Comparative harm: HbA1c increase", "question": "Are the definition, units, analysis time point and endpoint hierarchy for HbA1c verified?", "needed": "Material on the HbA1c outcome definition, units, time point and endpoint hierarchy, and their correspondence with the original plan", "role": "Required", "role_reason": "Needed to avoid reading the primary (1st) safety endpoint, HbA1c, as a secondary lipid result, diagnostic event or incidence rate.", "application_exception": "Keep the reported primary (1st) hierarchy separate from whether its prospective registration plan has been verified.", "criterion": "The between-group difference in change from baseline to week 16 in HbA1c, the %p unit, and its status as the original trial's primary (1st) safety endpoint are distinguished.", "basis": "C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / H01: M19 §19.1.2–19.2.4; detailed distinctions are internally designed / E03: M08 Table 8.2.a, M03 §3.2.4; internal application / E06: M08 Table 8.2.a, M04 §4.6.3; internal application. Reason for adapting this to comparative HbA1c harm: needed to avoid reading the primary (1st) safety endpoint, HbA1c, as a secondary lipid result, diagnostic event or incidence rate. No new clinical causality/grade judgment or official methodological procedure was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Compare the selected outcome's change, between-group direction and hierarchy with the original results, and consider other endpoints separately." }, { "item_id": "N13", "question_type": "Comparative harm: HbA1c increase", "question": "Are the actual laboratory measuring HbA1c and the scheduled visit times verified?", "needed": "The original testing schedule, laboratory and participant-specific records of completed measurements", "role": "Required", "role_reason": "Needed to distinguish repeated measurement time points from the single end-of-study outcome and clarify which follow-up period the result belongs to.", "application_exception": "Do not turn scheduled measurement times into a claim that completion/analysis data for every participant have been obtained.", "criterion": "The original material specifies the central laboratory and measurements at baseline and weeks 4·8·12·16.", "basis": "C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / H01: M19 §19.1.2–19.2.4; detailed distinctions are internally designed / H02: Design-specific harm questions in M19 §19.2; details of temporal relationships are internally designed / E03: M08 Table 8.2.a, M03 §3.2.4; internal application. Reason for adapting this to comparative HbA1c harm: needed to distinguish repeated measurement time points from the single end-of-study outcome and clarify which follow-up period the result belongs to. No new clinical causality/grade judgment or official methodological procedure was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Link scheduled measurements with actual completion records and examine the denominator at each time point." }, { "item_id": "N14", "question_type": "Comparative harm: HbA1c increase", "question": "Are the HbA1c assay method, equipment, standardization and interference assessment verified?", "needed": "Specifications for the central laboratory's HbA1c method, equipment, standardization, quality control and interference assessment", "role": "Required", "role_reason": "The description of a central laboratory alone cannot guarantee measurement standardization or the absence of interference by arm.", "application_exception": "Do not turn unverified assay details into invalidity of the entire result or confirmation of assay interference.", "criterion": "Material is available to verify the exact HbA1c method, equipment and standardization, and interference/measurement limitations by arm.", "basis": "H01: M19 §19.1.2–19.2.4; detailed distinctions are internally designed / E03: M08 Table 8.2.a, M03 §3.2.4; internal application. Reason for adapting this to comparative HbA1c harm: the description of a central laboratory alone cannot guarantee measurement standardization or the absence of interference by arm. No new clinical causality/grade judgment or official methodological procedure was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Compare assay conditions with collection at each time point, and examine whether evidence of measurement differences or interference actually exists." }, { "item_id": "N15", "question_type": "Comparative harm: HbA1c increase", "question": "Are the overall assigned/treated counts and selected-arm counts distinguished from the HbA1c analysis denominator?", "needed": "An arm-specific flow table for allocation, treatment, completion and endpoint analysis, and the original basis for the labels used", "role": "Required", "role_reason": "Needed to avoid substituting the overall sample or treated-arm counts for the analysis denominator of the selected HbA1c outcome.", "application_exception": "Preserve the original bytes of the structured group-count field name randomized_arm_counts and the manuscript's description of the treated groups; do not reinterpret them as the actual endpoint analysis n.", "criterion": "The overall counts of 148 assigned and 146 treated participants, the selected-arm counts of 52/49, and the unverified endpoint-specific analysis n are each explicitly distinguished.", "basis": "C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations for specific designs were developed internally / H06: M19 §19.1.2–19.2.4, M04 §4.6.3; internal application / E04: M08 §8.2.2, M15 §15.3.1; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid substituting the overall sample or treated-arm counts for the analysis denominator of the selected HbA1c outcome. No new clinical causality/grade judgment was made, and no official methodology was applied.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Compare the stage represented by each sample count with the outcome denominator, and record the overall, selected, and analysis populations separately." }, { "item_id": "N16", "question_type": "Comparative harm: HbA1c increase", "question": "Have the endpoint-specific HbA1c analysis n, handling of missing data, and variance of paired changes been verified?", "needed": "Endpoint-specific n by arm, reasons for and handling of missing data, individual repeated measurements, and change-variance data", "role": "Required", "role_reason": "This is needed to avoid filling in analysis denominators, variances, or intervals from the selected-arm counts of 52/49 and a rounded P value.", "application_exception": "Preserve the original missing values. Do not substitute arm-specific end-of-study SEs for change SD/SE or perform new calculations.", "criterion": "The HbA1c analysis n, handling of missing data, and SD/SE of paired changes for the selected comparison are linked to original data.", "basis": "C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations for specific designs were developed internally / H06: M19 §19.1.2–19.2.4, M04 §4.6.3; internal application / E04: M08 §8.2.2, M15 §15.3.1; internal application / E05: M15 §15.3.1–15.3.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid filling in analysis denominators, variances, or intervals from the selected-arm counts of 52/49 and a rounded P value. No new clinical causality/grade judgment was made, and no official methodology was applied.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Compare the analysis populations, missing data at each time point, and variance of paired changes with the original results tables; do not fill unverified information through calculation." }, { "item_id": "N17", "question_type": "Comparative harm: HbA1c increase", "question": "Have losses to follow-up, their reasons, and their effects on the endpoint been verified for the selected comparison?", "needed": "A table linking reasons and timing of attrition/discontinuation by arm with HbA1c missingness and its handling", "role": "Required", "role_reason": "This is needed to avoid treating reported attrition and HbA1c missingness as the same event, or applying the original historical rate as a new bias score.", "application_exception": "The expression 17/101=16.83% is an existing record and is not recalculated. Original scoring criteria such as 15% or 200 participants are not imposed as adequacy criteria for the new conditions.", "criterion": "Attrition counts, reasons by arm, timing, and their links to HbA1c missingness and its analytical impact are verified for the selected comparison.", "basis": "C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations for specific designs were developed internally / H06: M19 §19.1.2–19.2.4, M04 §4.6.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid treating reported attrition and HbA1c missingness as the same event, or applying the original historical rate as a new bias score. No new clinical causality/grade judgment was made, and no official methodology was applied.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Track treatment discontinuation, loss to follow-up, and missing measurements separately to assess which data remain for the selected outcome." }, { "item_id": "N18", "question_type": "Comparative harm: HbA1c increase", "question": "Does the authors' ITT designation agree with the actual effect of interest and analysis population?", "needed": "Analysis plan, inclusion/exclusion rules, between-group model, and definition of the effect of interest", "role": "Required", "role_reason": "This is needed to avoid treating a population that excludes untreated participants as ITT based on all randomized participants.", "application_exception": "Retain the authors' ITT wording while distinguishing it from actual exclusions and the effect of interest. Do not infer an adherence effect or an adjusted model.", "criterion": "Agreement is verified between the effect of assignment overall or the actual effect of interest and the analysis inclusion/exclusion rules and model.", "basis": "E04: M08 §8.2.2, M15 §15.3.1; internal application / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application / H06: M19 §19.1.2–19.2.4, M04 §4.6.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid treating a population that excludes untreated participants as ITT based on all randomized participants. No new clinical causality/grade judgment was made, and no official methodology was applied.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Compare the authors' designation with the actual analysis population to distinguish the add-on strategy's effect of interest, adherence effects, and the effects of exclusions." }, { "item_id": "N19", "question_type": "Comparative harm: HbA1c increase", "question": "Has attribution of the reported arm-specific HbA1c changes, P value, and existing arithmetic difference been verified?", "needed": "Arm-specific mean changes, the reported between-group test, a formal model-estimate table, and the original arithmetic record", "role": "Required", "role_reason": "This is needed to avoid turning the changes in both arms, the P value, and the arithmetic difference into different analyses or clinical risk rates.", "application_exception": "The original +0.31 %p is reused solely as historical arithmetic; no formal model estimate, formal CI, or individual risk rate is generated.", "criterion": "The selected comparison's +0.29 versus −0.02 %p, reported P=.048, and existing arithmetic +0.31 %p are each linked to their original locations and the nature of their analyses.", "basis": "C06: M03 §3.2.4, M15 §15.3.1–15.3.3; adaptations of outcomes to the specific question were developed internally / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application / E04: M08 §8.2.2, M15 §15.3.1; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid turning the changes in both arms, the P value, and the arithmetic difference into different analyses or clinical risk rates. No new clinical causality/grade judgment was made, and no official methodology was applied.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Link reported values to outcomes, time points, and analyses, distinguishing descriptive arithmetic from formal estimates without repeating the calculation." }, { "item_id": "N20", "question_type": "Comparative harm: HbA1c increase", "question": "Have the formal between-group HbA1c change estimate, SE, and CI been verified?", "needed": "A formal between-group change-estimate table, model, paired variance, denominator, and confidence interval", "role": "Required", "role_reason": "This is needed to avoid establishing the magnitude and precision of harm from significance or a simple mean difference alone.", "application_exception": "Do not reconstruct an interval or standardized effect using the rounded P=.048, end-of-study SEs, or 52/49.", "criterion": "The formal between-group change estimate and SE/CI appropriate to the selected comparison, time point, and analysis are verified from the original results.", "basis": "C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations for specific designs were developed internally / E04: M08 §8.2.2, M15 §15.3.1; internal application / E05: M15 §15.3.1–15.3.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid establishing the magnitude and precision of harm from significance or a simple mean difference alone. No new clinical causality/grade judgment was made, and no official methodology was applied.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Link the formal estimate and interval to the verified analysis to examine compatible magnitudes, leaving unverified information unverified." }, { "item_id": "N21", "question_type": "Comparative harm: HbA1c increase", "question": "Have the matching prospective registration, protocol, SAP, and handling of multiplicity been verified?", "needed": "The matching ADVENT registration, original protocol, SAP, and information on analysis changes/multiplicity", "role": "Required", "role_reason": "This is needed to avoid treating a reported primary (1st) endpoint as completed verification against the planned analysis.", "application_exception": "A null registration_id and an unobtained plan do not establish that the study was unregistered or selectively reported. Do not attach another registration or protocol to ADVENT.", "criterion": "Agreement or changes in endpoints, time points, models, and multiplicity between the matching prospective ADVENT plan and actual results can be verified.", "basis": "C09: M04 §4.5, §4.6.3; the limits of the current data conversion follow the user-defined scope and internal design / E06: M08 Table 8.2.a, M04 §4.6.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid treating a reported primary (1st) endpoint as completed verification against the planned analysis. No new clinical causality/grade judgment was made, and no official methodology was applied.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Compare the prospective plan with the results by endpoint, time point, and analysis, leaving unobtained information unverified." }, { "item_id": "N22", "question_type": "Comparative harm: HbA1c increase", "question": "Has a validated threshold for the clinical importance of this HbA1c difference been identified?", "needed": "A validated importance threshold, paired variance, and patient-importance information for this HbA1c comparison", "role": "Required; interpretation of magnitude", "role_reason": "This is needed to distinguish an increase signal from the magnitude of clinically important deterioration.", "application_exception": "Do not turn EX into no numerical value, no effect, or failure to meet a threshold, and do not invent an arbitrary MCID, minimum n, or duration.", "criterion": "An important-difference threshold or a justified interpretation of the corresponding standardized effect appropriate to this population, add-on strategy, and duration is verified.", "basis": "E05: M15 §15.3.1–15.3.3; internal application / H09: Chamgap's own interpretive boundaries. The M19 principles are referenced; no official causality tool was applied. Reason for adapting this to the comparative HbA1c harm question: This is needed to distinguish an increase signal from the magnitude of clinically important deterioration. No new clinical causality/grade judgment was made, and no official methodology was applied.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Interpret verified evidence on importance against the formal change estimate/interval; do not replace an importance threshold with conventional significance alone." }, { "item_id": "N23", "question_type": "Comparative harm: HbA1c increase", "question": "For the 1,000 mg arm in the same ADVENT trial, have the HbA1c difference and uncertainty been verified?", "needed": "The 1,000 mg arm's HbA1c results, between-group estimate/interval, and denominator in the same trial", "role": "Supplementary; required for interpreting dose-related/opposing findings", "role_reason": "This is needed to avoid turning another dose in the same trial into independent replication or evidence of safety at all lower doses.", "application_exception": "Do not interpret nonsignificance at P=.16 as an effect of 0, equivalence, a harmless dose, or an established dose–response relationship.", "criterion": "For the 1,000 mg arm, the actual between-group HbA1c difference, denominator, and interval are verified and distinguished from the selected 1,500 mg comparison.", "basis": "C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses was developed internally / E07: M04 §4.6.1–4.6.2, M15 §15.3.1; internal application / E08: M03 §3.2.1–3.2.4; details of dose, persistence, and effect modification were developed internally / H07: M04 §4.6.1–4.6.2; adaptation for harm data was developed internally. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid turning another dose in the same trial into independent replication or evidence of safety at all lower doses. No new clinical causality/grade judgment was made, and no official methodology was applied.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Compare the actual results and analyses by dose, retaining them as context from the same family; do not newly calculate direct dose effects or a harmless-dose threshold." }, { "item_id": "N24", "question_type": "Comparative harm: HbA1c increase", "question": "For the 1,000 mg arm, does baseline HbA1c agree between the table and abstract?", "needed": "The corresponding value in the original Table 1 and abstract, and any correction or author explanation", "role": "Supplementary; required for verifying a conflict concerning the same fact", "role_reason": "This is needed to avoid arbitrarily correcting conflicting values or claiming that they have been reconciled as different endpoints.", "application_exception": "Do not treat successful documentation of a conflict as fulfillment of the data-consistency condition. Do not change values for the currently selected arms.", "criterion": "For the same 1,000 mg arm, baseline HbA1c agrees between the table and abstract, or the difference is resolved by evidence of a correction.", "basis": "C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses was developed internally / E03: M08 Table 8.2.a, M03 §3.2.4; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid arbitrarily correcting conflicting values or claiming that they have been reconciled as different endpoints. No new clinical causality/grade judgment was made, and no official methodology was applied.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Compare the original locations for the same fact side by side; resolve differences only when correction evidence is available, retaining the previous values." }, { "item_id": "N25", "question_type": "Comparative harm: HbA1c increase", "question": "Has the original material for the no-change conference presentation cited by the study report been verified?", "needed": "The original conference abstract, presentation identity, population/intervention, results, and trial-linkage information", "role": "Supplementary; required for interpreting replication/opposing evidence", "role_reason": "This is needed to avoid elevating the study report's secondhand citation to a newly read independent presentation result.", "application_exception": "Do not assign a unique trial count or participant count to a presentation whose relationship to the same trial or another family is unverified.", "criterion": "Material is available to directly verify the identity, population, intervention, HbA1c results, and family relationships of the original presentation.", "basis": "C02: M04 §4.6.1–4.6.2: distinction between studies and reports; internal application to cohort/outcome linkage / C03: M04 §4.5–4.6: data-collection/selection principles; the distinction between access and reading and the hyperlink conventions were developed internally / C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses was developed internally / H07: M04 §4.6.1–4.6.2; adaptation for harm data was developed internally. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid elevating the study report's secondhand citation to a newly read independent presentation result. No new clinical causality/grade judgment was made, and no official methodology was applied.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Verify the relationship between the original presentation and study report to distinguish same-family, different-family, and unknown relationships; do not count a secondhand citation as independent replication." }, { "item_id": "N26", "question_type": "Comparative harm: HbA1c increase", "question": "Have the actual formulation, comparison, timing, and between-group HbA1c results of ADMIT been verified?", "needed": "ADMIT treatment/run-in, factorial co-interventions, diabetic-subgroup results tables, denominators, tests/intervals, and corrections", "role": "Supplementary; required for interpreting indirect/opposing comparisons", "role_reason": "This is needed to avoid turning within-arm maintenance in IR ADMIT into a null between-group effect for NIASPAN ER or replication of the exact comparison.", "application_exception": "Retain the ADMIT abstract/table P-value discrepancy as originally recorded; do not newly fill in figures absent from the current retained version.", "criterion": "The IR formulation, different dose/run-in/population, time point of interest, between-group results, and uncertainty in ADMIT are verified.", "basis": "C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations were developed internally / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; adaptations of outcomes to the specific question were developed internally / C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses was developed internally / E04: M08 §8.2.2, M15 §15.3.1; internal application / E07: M04 §4.6.1–4.6.2, M15 §15.3.1; internal application / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid turning within-arm maintenance in IR ADMIT into a null between-group effect for NIASPAN ER or replication of the exact comparison. No new clinical causality/grade judgment was made, and no official methodology was applied.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Compare formulation, population, co-interventions, and the effect of interest over time to distinguish within-arm from between-arm results; do not count them together as direct ER comparisons." }, { "item_id": "N27", "question_type": "Comparative harm: HbA1c increase", "question": "Have the actual release formulation, measurements, and period-specific contrasts in the Garg crossover trial been verified?", "needed": "The product release formulation, assay method, crossover sequence/periods, paired results, and denominators in the original Garg full text", "role": "Supplementary; required for interpreting indirect evidence", "role_reason": "This is needed to avoid automatically equating the nicotinic acid name and glycosylated hemoglobin results with the selected ER HbA1c change.", "application_exception": "Do not calculate the 13-participant crossover trial as an independent-arm design or treat glycosylated hemoglobin as a verified equivalent HbA1c assay.", "criterion": "The crossover trial's release formulation, measurement method, paired period comparison, and denominator/interval are verified.", "basis": "C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations were developed internally / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; adaptations of outcomes to the specific question were developed internally / C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; adaptations for specific designs were developed internally / E04: M08 §8.2.2, M15 §15.3.1; internal application / E07: M04 §4.6.1–4.6.2, M15 §15.3.1; internal application / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid automatically equating the nicotinic acid name and glycosylated hemoglobin results with the selected ER HbA1c change. No new clinical causality/grade judgment was made, and no official methodology was applied.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Examine the actual periods and paired contrasts in the crossover design and assay equivalence; do not calculate an independent-arm effect." }, { "item_id": "N28", "question_type": "Comparative harm: HbA1c increase", "question": "Have the ingredient, product, and comparison in the report of improvement with low-dose niacin and sitagliptin been verified?", "needed": "Ingredient/product specifications, sitagliptin/chromium arm composition, comparator, and HbA1c results tables for the Karim trial", "role": "Supplementary; required for determining the applicability of opposing evidence", "role_reason": "This is needed to retain results in the opposite direction while preventing findings with a different dose and co-treatment from being repurposed for the selected prescription ER comparison.", "application_exception": "Do not fill in NIASPAN for the unverified nicotinic acid/amide identity and product of the 14 mg/day niacin.", "criterion": "The actual molecule, product, dose, co-treatment arms, comparator, and comparative scope of the HbA1c results are verified.", "basis": "C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations were developed internally / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; adaptations of outcomes to the specific question were developed internally / C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses was developed internally / E02: M03 §3.2.3, M08 §8.2.2–8.2.3; internal application / E07: M04 §4.6.1–4.6.2, M15 §15.3.1; internal application / H03: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application. Reason for adapting this to the comparative HbA1c harm question: This is needed to retain results in the opposite direction while preventing findings with a different dose and co-treatment from being repurposed for the selected prescription ER comparison. No new clinical causality/grade judgment was made, and no official methodology was applied.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Compare the molecule, product, co-treatment, comparator, and direction of results, preserving them separately from the selected comparison." }, { "item_id": "N29", "question_type": "Comparative harm: HbA1c increase", "question": "Has evidence of independent replication of the exact NIASPAN comparison been verified?", "needed": "Links between unique trials and reports, and independent results tables, for the exact comparison", "role": "Supplementary; required for interpreting replication/generalizability", "role_reason": "This is needed to avoid counting reports of the same dose arms, regulatory secondhand citations, reviews, or registrations as independent replication trials.", "application_exception": "Preserve the original R1 and the single direct family. Do not newly judge the number of studies worldwide, the total number of unique participants, or the absence of replication.", "criterion": "Results from an independent family matching the product, dose, population, policy, time point, and HbA1c comparison are directly verified.", "basis": "C02: M04 §4.6.1–4.6.2: distinction between studies and reports; internal application to cohort/outcome linkage / E07: M04 §4.6.1–4.6.2, M15 §15.3.1; internal application / H07: M04 §4.6.1–4.6.2; adaptation for harm data was developed internally. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid counting reports of the same dose arms, regulatory secondhand citations, reviews, or registrations as independent replication trials. No new clinical causality/grade judgment was made, and no official methodology was applied.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Link reports to trial families, endpoints, and analyses to distinguish same, different, and unknown relationships; leave the undetermined number of unique studies without a value." }, { "item_id": "N30", "question_type": "Comparative harm: HbA1c increase", "question": "Have funding, manufacturer-affiliated authors, and disclosed conflicts of interest in the direct trial been verified?", "needed": "Original funding information, author affiliations, product supply, speaking/stock/employment relationships, and COI disclosures", "role": "Supplementary; required for interpreting independence", "role_reason": "This is needed to avoid penalizing manufacturer support/author relationships again as trial-method bias, or automatically deleting the data.", "application_exception": "The presence of Kos support is not used to declare the figures invalid, nor as proof of independent funding or independent replication.", "criterion": "Funding, author affiliations, and disclosed relationships such as speaking/stock interests in the core trial are linked to their original locations.", "basis": "C10: Chamgap's own criteria for independence and attribution. The official methodological sections used in this pilot do not warrant all of these detailed items. Reason for adapting this to the comparative HbA1c harm question: This is needed to avoid penalizing manufacturer support/author relationships again as trial-method bias, or automatically deleting the data. No new clinical causality/grade judgment was made, and no official methodology was applied.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Distinguish and verify each source of funding, employment relationship, and disclosure, and examine the scope of claims of independence." }, { "item_id": "N31", "question_type": "Comparative harm: HbA1c increase", "question": "Can the products and versions in the official ER documents, and their differences from the historical trial, be verified?", "needed": "Products, versions, dates, description/warning sections in the DailyMed/FDA documents, and information linking them to the trial product", "role": "Supplementary; required for interpreting official safety information", "role_reason": "Needed to avoid automatically treating the 2026 generic label and the 2020 NIASPAN file as manufacturing details for the original trial, the latest documents, or estimates of the trial effect.", "application_exception": "The current official webpages/PDFs are not newly read, and their currency or jurisdiction-specific approvals are not rechecked.", "criterion": "The products, versions, and review scope of the official generic document available at the reference date and the historical NIASPAN document are distinguished.", "basis": "C05: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptations are internally designed / C09: M04 §4.5, §4.6.3; the limits of the current data conversion follow the user-defined scope and internal design / H08: M19 §19.1.2–19.2.4; internal application / E10: M19 §19.1.2–19.2.4; internal application. Reason for adaptation to the comparative HbA1c harm question: needed to avoid automatically treating the 2026 generic label and the 2020 NIASPAN file as manufacturing details for the original trial, the latest documents, or estimates of the trial effect. No new clinical causality/grade judgment or application of an official method was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Compare official documents by version, product, and date to distinguish exposure in the historical trial from the safety background." }, { "item_id": "N32", "question_type": "Comparative harm: HbA1c increase", "question": "Can the collection of other harms, discontinuations, and exposure denominators in the same trial be verified?", "needed": "Trial AE definitions, collection procedures, group-specific exposure/events/discontinuations, duration data, and original locations of official warnings", "role": "Supplementary; required for interpreting overall safety", "role_reason": "Needed to avoid turning the failure to detect major liver or muscle events in a short trial, together with official warnings, into an event rate of 0 or overall safety.", "application_exception": "H04 is adapted only to data requirements for the frequency of separate events, such as liver/muscle events; it is not imposed as a mandatory incidence requirement for the continuous mean change in HbA1c.", "criterion": "Definitions, collection, group-specific person/event counts, durations, and discontinuations for other AEs in the same population under the same exposure are verified.", "basis": "H01: M19 §19.1.2–19.2.4; detailed distinctions are internally designed / H04: M19 §19.1.2–19.2.4; internal application / H06: M19 §19.1.2–19.2.4, M04 §4.6.3; internal application / E10: M19 §19.1.2–19.2.4; internal application. Reason for adaptation to the comparative HbA1c harm question: needed to avoid turning the failure to detect major liver or muscle events in a short trial, together with official warnings, into an event rate of 0 or overall safety. No new clinical causality/grade judgment or application of an official method was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Distinguish continuous HbA1c changes from separate AEs when comparing collection, exposure denominators, and person/event counts; do not fill unreported information with 0." }, { "item_id": "N33", "question_type": "Comparative harm: HbA1c increase", "question": "Can data on persistent HbA1c effects, long-term complications, and rare harms be verified?", "needed": "Exposure/follow-up data on HbA1c after discontinuation, long-term complications, rare events, and vulnerable groups", "role": "Supplementary; required for an extension to long-term/overall safety", "role_reason": "Needed to avoid establishing persistent effects, rare events, or risks in excluded vulnerable groups from short-term mean changes.", "application_exception": "Not every long-term study is unconditionally required to answer the narrow 16-week HbA1c claim, but gaps in extended claims remain explicit.", "criterion": "Appropriate follow-up data are available to verify persistent/long-term and rare harms for the selected population and product.", "basis": "H08: M19 §19.1.2–19.2.4; internal application / E08: M03 §3.2.1–3.2.4; details of dose, persistence, and effect modification are internally designed. Reason for adaptation to the comparative HbA1c harm question: needed to avoid establishing persistent effects, rare events, or risks in excluded vulnerable groups from short-term mean changes. No new clinical causality/grade judgment or application of an official method was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Distinguish long-term follow-up, repeated-measurement, and event-collection methods suited to the question; do not interpret short-term nondetection as long-term safety." }, { "item_id": "N34", "question_type": "Comparative harm: HbA1c increase", "question": "Can the body text, results, and correspondence to ADVENT of the registry leads be verified?", "needed": "Official body text/history, results, and verified linkage data for DRKS00030865, NCT00108485, and NCT06378125", "role": "Supplementary; required for interpreting registrations/unpublished results", "role_reason": "Needed to avoid elevating registry completion/termination status, mirrors, or a JS shell to verified HbA1c results or replication of ADVENT.", "application_exception": "Do not assert that NCT06378125 and DRKS00030865 are the same registration without a verified cross-link. Do not display historical access failures as current failures.", "criterion": "The official body text, results, registry links, and correspondence to the selected ADVENT comparison are directly verified.", "basis": "C02: the distinction between studies and reports in M04 §4.6.1–4.6.2; internal application to cohort/outcome linkage / C03: the data-collection/selection principles in M04 §4.5–4.6; the distinction between access and reading, and the hyperlink conventions, are internally designed / C09: M04 §4.5, §4.6.3; the limits of the current data conversion follow the user-defined scope and internal design / E06: M08 Table 8.2.a, M04 §4.6.3; internal application / H07: M04 §4.6.1–4.6.2; adaptation for harm data is internally designed. Reason for adaptation to the comparative HbA1c harm question: needed to avoid elevating registry completion/termination status, mirrors, or a JS shell to verified HbA1c results or replication of ADVENT. No new clinical causality/grade judgment or application of an official method was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Compare each registration's population, release product, endpoints, results, and links to distinguish plans/status/mirror leads from clinical results." }, { "item_id": "N35", "question_type": "Comparative harm: HbA1c increase", "question": "Can the actual body text, scope, and family relationships of the review, protocol, and expression-of-concern notice be verified?", "needed": "The review's included trials/results tables, protocol body text, content/scope of the expression-of-concern notice, and document links", "role": "Supplementary; required for interpreting indirect evidence/editorial history", "role_reason": "Needed to avoid repurposing the existence of a review, an indexed protocol, or an expression-of-concern lead as confirmation of results or evidence of an ADVENT defect.", "application_exception": "Keep the spelling in the actual returned S13 link byte-for-byte. Do not add scope or ADVENT relevance without having read the original text of the expression-of-concern notice.", "criterion": "The actual content of the S11 included trials, S12 plans, and S13 notice, and their relationships to the corresponding documents/trials, are verified.", "basis": "C02: the distinction between studies and reports in M04 §4.6.1–4.6.2; internal application to cohort/outcome linkage / C03: the data-collection/selection principles in M04 §4.5–4.6; the distinction between access and reading, and the hyperlink conventions, are internally designed / C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed / C09: M04 §4.5, §4.6.3; the limits of the current data conversion follow the user-defined scope and internal design / E06: M08 Table 8.2.a, M04 §4.6.3; internal application / H07: M04 §4.6.1–4.6.2; adaptation for harm data is internally designed. Reason for adaptation to the comparative HbA1c harm question: needed to avoid repurposing the existence of a review, an indexed protocol, or an expression-of-concern lead as confirmation of results or evidence of an ADVENT defect. No new clinical causality/grade judgment or application of an official method was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Distinguish results, plans, and editorial notices, attributing them only to the corresponding documents; do not count them as independent trials or extend them to unrelated trials." }, { "item_id": "N36", "question_type": "Comparative harm: HbA1c increase", "question": "Does this HbA1c comparison also answer questions about incident diabetes or cardiovascular/complication events?", "needed": "Definitions, denominators, follow-up, and between-group results for incident diabetes and cardiovascular/complication events in the selected comparison", "role": "Supplementary; required for an extension to clinical events", "role_reason": "Needed to avoid treating a mean difference in a surrogate as an increase in event incidence or long-term complications.", "application_exception": "Because the original question concerns HbA1c change itself, event trials are not imposed as an invariably mandatory condition for verifying that result.", "criterion": "Direct results are available to address the separate clinical-event question in the same population with the same product and comparison.", "basis": "C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / E09: M03 §3.2.4; internally defined extension boundaries / H08: M19 §19.1.2–19.2.4; internal application / H09: Chamgap's own interpretive boundaries. The M19 principles are referenced; no official causality tool was applied. Reason for adaptation to the comparative HbA1c harm question: needed to avoid treating a mean difference in a surrogate as an increase in event incidence or long-term complications. No new clinical causality/grade judgment or application of an official method was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Review appropriate follow-up that measures and analyzes HbA1c and event endpoints separately, and do not estimate event effects from the surrogate alone." }, { "item_id": "N37", "question_type": "Comparative harm: HbA1c increase", "question": "Are current summary reading, each material's historical access/access date, and current external nonreading distinguished?", "needed": "Actual access, acquisition, and reading events for each material, original locations and dates, and hashes of the retained inputs", "role": "Required", "role_reason": "Needed to avoid treating historical full-text/abstract/access-failure records (full_text/abstract/access_failure) and original access dates as actions performed in this review.", "application_exception": "Do not describe current unattempted external access as access failure; use a historical access date only for a bibliographic record (citation) that actually has an access_date. Do not mark older separate files as having been read merely because they are referenced.", "criterion": "Local retained-summary reading, historical access/access dates for the 13 bibliographic records (citation), the original review date, and current unattempted/unread external access are recorded separately.", "basis": "C03: the data-collection/selection principles in M04 §4.5–4.6; the distinction between access and reading, and the hyperlink conventions, are internally designed / C09: M04 §4.5, §4.6.3; the limits of the current data conversion follow the user-defined scope and internal design. Reason for adaptation to the comparative HbA1c harm question: needed to avoid treating historical full-text/abstract/access-failure records (full_text/abstract/access_failure) and original access dates as actions performed in this review. No new clinical causality/grade judgment or application of an official method was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "Review actions for each material by event/date, and add an actual new external-reading event only when that reading is authorized." }, { "item_id": "N38", "question_type": "Comparative harm: HbA1c increase", "question": "Are the original C46, 7 axes, document quality, and new condition statuses distinguished in what they describe?", "needed": "Original records of the assessment, axes, score meaning, document quality, and version", "role": "Required", "role_reason": "Needed to avoid reusing the original clinical-harm grade as a safety grade, risk rate, document-quality grade, or criterion-fulfillment rate.", "application_exception": "Preserve the original missing values, false values, axes, and score unchanged; do not change them to F or efficacy not_applicable merely because this is a harm claim.", "criterion": "The clinical-harm claim/increase designation (clinical_harm_claim/increase), C46 and B/S/R1/I0/EX/B2/CX, and the meaning of document self-review grade A are each linked to their original locations.", "basis": "C01: the question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed / C09: M04 §4.5, §4.6.3; the limits of the current data conversion follow the user-defined scope and internal design / H09: Chamgap's own interpretive boundaries. The M19 principles are referenced; no official causality tool was applied. Reason for adaptation to the comparative HbA1c harm question: needed to avoid reusing the original clinical-harm grade as a safety grade, risk rate, document-quality grade, or criterion-fulfillment rate. No new clinical causality/grade judgment or application of an official method was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "If a correction becomes necessary, preserve the original event and before/after values, and review criterion revision and changes to the clinical assessment as separate tasks." }, { "item_id": "N39", "question_type": "Comparative harm: HbA1c increase", "question": "Are the current verification scope, evidence reference date, original server metadata, and update events stated?", "needed": "Evidence/review dates, actual retained search/selection records, versions, and update/correction events", "role": "Required", "role_reason": "Needed to avoid overstating conversion of retained materials as a current comprehensive search, completed public release, or absence of studies worldwide.", "application_exception": "Distinguish the historical dates in evidence_cutoff/verified_date from the current review date, and do not interpret the original first-publication date or the missing deployment timestamp (deployed_at, null) as a new deployment event.", "criterion": "The original reference date of 2026-09-15, the scope of review of current retained inputs, actual review dates, unverified information, update events, and nondeployment are distinguished.", "basis": "C09: M04 §4.5, §4.6.3; the limits of the current data conversion follow the user-defined scope and internal design / E06: M08 Table 8.2.a, M04 §4.6.3; internal application. Reason for adaptation to the comparative HbA1c harm question: needed to avoid overstating conversion of retained materials as a current comprehensive search, completed public release, or absence of studies worldwide. No new clinical causality/grade judgment or application of an official method was performed.", "condition_origin": "The internally developed criteria for this known development case, whose material has already been read, are frozen through a separate explicit instruction. This is not automatic copying, blinding, clinical preregistration or official methodological certification.", "proposed_research": "If authorized new materials become available, compare their identities, dates, original locations, and access levels, and review the linked conditions' observations and status reasons again." } ], "language": "en", "translation_date": "2026-11-01" }